Stoke Therapeutics, Inc. (NASDAQ:STOK) to Post Q1 2024 Earnings of ($0.61) Per Share, Wedbush Forecasts

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Wedbush decreased their Q1 2024 earnings per share (EPS) estimates for Stoke Therapeutics in a note issued to investors on Tuesday, March 26th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.61) for the quarter, down from their previous forecast of ($0.57). Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.65) EPS, Q4 2024 earnings at ($0.60) EPS, FY2024 earnings at ($2.48) EPS, FY2026 earnings at ($2.97) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at $1.39 EPS.

STOK has been the topic of a number of other reports. Canaccord Genuity Group raised their price target on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday. Needham & Company LLC raised their target price on Stoke Therapeutics from $14.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. raised their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $13.50 on Thursday. The firm has a market capitalization of $625.05 million, a price-to-earnings ratio of -5.52 and a beta of 0.68. Stoke Therapeutics has a one year low of $3.35 and a one year high of $16.40. The stock’s fifty day moving average is $6.07 and its 200-day moving average is $5.02.

Insider Buying and Selling

In related news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at approximately $423,035. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the sale, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,615 shares of company stock worth $212,852. 12.30% of the stock is currently owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of STOK. Ensign Peak Advisors Inc bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $25,000. Point72 Hong Kong Ltd bought a new stake in Stoke Therapeutics in the first quarter valued at $27,000. Great West Life Assurance Co. Can grew its position in Stoke Therapeutics by 46.7% in the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after acquiring an additional 1,078 shares during the period. Dorsey & Whitney Trust CO LLC bought a new stake in Stoke Therapeutics in the third quarter valued at $43,000. Finally, UBS Group AG bought a new stake in Stoke Therapeutics in the third quarter valued at $47,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.